HC Wainwright & Co. Reiterates Buy on Corcept Therapeutics, Maintains $165 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 90.1%

Neg 0% Neu 90.1% Pos 0%

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Corcept Therapeutics (NASDAQ:CORT) with a Buy and maintains $165 price target.